<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353534</url>
  </required_header>
  <id_info>
    <org_study_id>IC82-102</org_study_id>
    <nct_id>NCT01353534</nct_id>
  </id_info>
  <brief_title>Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine</brief_title>
  <official_title>A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Groups 1 to 3 will receive two vaccinations on Day 0 and Day 21. Group 1 will receive 3.8µg&#xD;
      A/H5N1 antigen formulated with AS03 adjuvant, administered by IM injection. Group 2 will&#xD;
      receive 15µg A/H5N1 by IM alone. Group 3 will also receive 15µg A/H5N1 antigen administered&#xD;
      IM but followed by the topical application of a VEP at the vaccination site. Group 4 will&#xD;
      receive a single vaccination on Day 0 of 30µg A/H5N1antigen by IM, followed by application of&#xD;
      a VEP at the vaccination site.&#xD;
&#xD;
      The VEP (Vaccine Enhancement Patch) contains 50 mcg LT (heat-labile enterotoxin of E. coli)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate hemagglutination inhibition (HI) immune responses</measure>
    <time_frame>Day 42</time_frame>
    <description>Evaluate hemagglutination inhibition (HI) immune responses to two doses of 15μg A/H5N1 achieved in the antigen plus VEP group versus the antigen alone group (Group 3 vs. Group 2) at Day 42 using standard serological parameters (Geometric Mean Titer [GMT], Geometric Mean Fold Ratio [GMFR], seroconversion and seroprotection).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of 15µg and 30µg IM A/H5N1 antigen administered with the 50µg VEP</measure>
    <time_frame>8 months</time_frame>
    <description>Comprehensive assessment of solicited and non-solicited local (vaccination site) and systemic adverse events (AEs) Safety follow-up through six months after last vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize HI immune responses</measure>
    <time_frame>8 months</time_frame>
    <description>Characterize HI immune responses in the 15µg A/H5N1 antigen alone group (Group 2) and the 15µg A/H5N1 antigen plus VEP group (Group 3) to determine if levels meet or exceed EMA CPMP/BWP/214/96 criteria for immunogenicity:&#xD;
The percent of subjects achieving seroconversion for HI antibody titer should meet or exceed 40%&#xD;
The percent of subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 70%&#xD;
GMT increase &gt; 2.5</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.8 mcg with AS03 adjuvant at D0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg at D0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg + 50 mcg VEP at D0 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg + 50 mcg VEP at D0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 Antigen</intervention_name>
    <description>A/H5N1 Antigen</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaccine Enhancement Patch</intervention_name>
    <description>Vaccine Enhancement Patch</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males or females 18-49 years of age (inclusive)&#xD;
&#xD;
          -  signed Informed Consent&#xD;
&#xD;
          -  Women who are not post-menopausal or surgically sterile must have a negative serum or&#xD;
             urine pregnancy test at screening and at all in-clinic visits with understanding to&#xD;
             not become pregnant over the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities at screening&#xD;
&#xD;
          -  abnormalities at physical examination&#xD;
&#xD;
          -  known allergies to any component of the A/H5N1 antigen&#xD;
&#xD;
          -  known egg protein allergy&#xD;
&#xD;
          -  known allergies to adhesives&#xD;
&#xD;
          -  known coagulation disorders&#xD;
&#xD;
          -  use of any anticoagulant medication within 30 days prior to vaccination or planned&#xD;
             usage during the study period&#xD;
&#xD;
          -  participated in research involving investigational product within 30 days before&#xD;
             planned date of vaccination or planned participation during study period&#xD;
&#xD;
          -  donated or received blood or blood products such as plasma within the three months&#xD;
             before planned date of vaccination or planned donation or use during the study period&#xD;
&#xD;
          -  received or planned receipt of seasonal influenza vaccine during the study period&#xD;
&#xD;
          -  received any licensed vaccines within 2 weeks (inactivated vaccines) or 4 weeks (live&#xD;
             vaccines) prior to planned date of vaccination&#xD;
&#xD;
          -  planned receipt of any licensed vaccine during the first 42 days on study&#xD;
&#xD;
          -  previous or planned vaccination with any vaccine containing an oil in water emulsion&#xD;
             adjuvant&#xD;
&#xD;
          -  previous or planned vaccination with pandemic vaccine against A/H5N1 or previous&#xD;
             proven contact with A/H5N1 wild type virus&#xD;
&#xD;
          -  ever received investigational enterotoxigenic E. coli LT, or LT (R192G) or NasalFlu,&#xD;
             Berna Biotech, Ltd. Ever received cholera toxin or vaccine&#xD;
&#xD;
          -  Recent or regular use of oral, topical or injected steroid medications within 30 days&#xD;
             prior to vaccination or planned use during the study period.&#xD;
&#xD;
          -  Use of immunosuppressive systemic steroid medications including inhaled steroids&#xD;
             within three months prior to vaccination or planned use during the study period&#xD;
&#xD;
          -  Comorbid conditions or treatments that are immunosuppressive, including cancer,&#xD;
             diabetes, and end-stage renal disease, as determined by the Investigator&#xD;
&#xD;
          -  positive serology for HIV-1, HIV-2, HBsAg, or HCV&#xD;
&#xD;
          -  history of severe atopy&#xD;
&#xD;
          -  medical history of acute or chronic skin disease at vaccination area&#xD;
&#xD;
          -  active skin allergy&#xD;
&#xD;
          -  signs of acute skin infection, sunburn or skin abnormalities at the vaccination area&#xD;
             including fungal infections, severe acne, active contact dermatitis, or a history of&#xD;
             keloid formation&#xD;
&#xD;
          -  hirsute at vaccination area&#xD;
&#xD;
          -  artificial tanning over the duration of the study including the screening period&#xD;
&#xD;
          -  visible tattoos or marks at the vaccination area that would prevent appropriate&#xD;
             dermatologic monitoring of the vaccination site&#xD;
&#xD;
          -  fever greater than or equal to 38.0°C at the time of planned vaccination&#xD;
&#xD;
          -  suspicion of or recent history of alcohol or substance abuse&#xD;
&#xD;
          -  women who are pregnant or breastfeeding&#xD;
&#xD;
          -  acute illness at screening or at the time of planned vaccination&#xD;
&#xD;
          -  ever had a serious reaction to prior influenza vaccination&#xD;
&#xD;
          -  developed a neurological disorder following a previous influenza vaccination or have&#xD;
             any acute and evolving neurological disorder&#xD;
&#xD;
          -  employee of the investigational site or sponsor&#xD;
&#xD;
          -  history of employment in bird or poultry industries or considerable exposure to birds&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Privatklinik Leech</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University - Campus Drie Eiken</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2011</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity and Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

